Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [41] Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
    Goodman, Rachel S.
    Jung, Seungyeon
    Balko, Justin M.
    Johnson, Douglas B.
    [J]. IMMUNOLOGICAL REVIEWS, 2023, 318 (01) : 157 - 166
  • [42] Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
    Zhan, Mei
    Long, Qinran
    He, Jinhan
    Huang, Litao
    Wu, Bin
    Xu, Haixia
    Mo, Li
    Xu, Ting
    [J]. FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [43] Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
    Hung, Hao-Chien
    Lee, Jin-Chiao
    Wang, Yu-Chao
    Cheng, Chih-Hsien
    Wu, Tsung-Han
    Lee, Chen-Fang
    Wu, Ting-Jung
    Chou, Hong-Shiue
    Chan, Kun-Ming
    Lee, Wei-Chen
    [J]. CANCERS, 2021, 13 (07)
  • [44] Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
    Sophia Bylsma
    Karen Yun
    Sandip Patel
    Michael J Dennis
    [J]. Current Treatment Options in Oncology, 2022, 23 : 1153 - 1168
  • [45] Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
    Bylsma, Sophia
    Yun, Karen
    Patel, Sandip
    Dennis, Michael J.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (09) : 1153 - 1168
  • [46] Immunotherapy in Older Adults with Cancer
    Richard Curtis Godby
    Douglas B. Johnson
    Grant R. Williams
    [J]. Current Oncology Reports, 2019, 21
  • [47] Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
    Kanjanapan, Yada
    Yip, Desmond
    [J]. CANCER MEDICINE, 2020, 9 (23): : 9027 - 9035
  • [48] Immunotherapy in Older Adults With Cancer
    Presley, Carolyn J.
    Gomes, Fabio
    Burd, Christin E.
    Kanesvaran, Ravindran
    Wong, Melisa L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (19) : 2115 - +
  • [49] Immunotherapy in Older Adults with Cancer
    Godby, Richard Curtis
    Johnson, Douglas B.
    Williams, Grant R.
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (07)
  • [50] Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
    Yan, Xinyu
    Zhang, Shouyue
    Deng, Yun
    Wang, Peiqi
    Hou, Qianqian
    Xu, Heng
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9